Your career starts on Magnet.me
Create a profile and receive smart job recommendations based on your liked jobs.
Summary
In 2026, Novartis aims to launch an innovative drug in the field of chronic spontaneous urticaria (CSU), with subsequent line extensions in underserved disease areas in the years to follow.
The launch excellence manager (LEM) is an early commercial lead that drives, together with a cross-functional team, the launch strategy for this priority pipeline asset in the Netherlands.
The LEM orchestrates the cross-functional work in the Dutch market. This LEM position has two important priorities: (re-)shaping and broadening the CSU market and paving the way for a successful launch of the priority pipeline asset in dermatology. Must-haves are a strategic and agile mindset, external focus and proactivity in seizing opportunities that enable access and adoption.
About the Role
Major accountabilities:
Key performance indicators:
In compliance with local functional business requirements:
Minimum Requirements:
Work Experience:
Skills:
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each other. Combining to achieve breakthroughs that change patients’ lives. Ready to create a brighter future together?
Novartis is committed to building an outstanding, inclusive work environment and diverse teams' representative of the patients and communities we serve.
Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
Change language to: Dutch
This page is optimised for people from the Netherlands. View the version optimised for people from the UK.